†These authors contributed equally.
Background: A statin alone or non-statins as add-ons have been
introduced to intensive low-density lipoprotein cholesterol (LDL-C) -lowering
therapy in patients at risk for high cardiovascular disease (CVD). The purpose of
this study was to evaluate the effectiveness and safety of different
rosuvastatin-based regimens for patients at high risk. Methods: Three
hundred patients at high CVD risk were randomly assigned to the statin group
(rosuvastatin, 20 mg/d), statin_EZ group (statin 10 mg/d + ezetimibe 10 mg/d),
statin_pcsk group (statin 10 mg/d + alirocumab 75 mg/2 weeks) or combine3 group
(statin 10 mg/d + ezetimibe 10 mg/d + alirocumab 75 mg/2 weeks). The primary
outcome measure was cholesterol levels after 24 weeks of follow-up. Secondary
outcomes included safety markers and the proportion of patients achieving the 70
mg/dL (1.8 mmol/L) target for LDL-C. A logistic regression model was performed to
explore the factors affecting lipid target achievement. Results: The
total cholesterol (TC) and LDL-C levels in the four groups after treatment were
significantly lower than those before treatment. TC and LDL-C levels after
treatment were significantly different among the four groups (p